Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature

Sopida Thipsawat

Abstract
Type 2 diabetes mellitus is a pathology of heterogeneous etiology characterized by hyperglycemia resulting from lack of insulin action, insulin secretion, or both, and the population with diabetes mellitus is predicted to be about 439 million worldwide by 2030. Prolong diabetes has been related with microvascular complications especially diabetic nephropathy. DN is the most common complication of type 2 diabetes mellitus, and it is the leading cause of end-stage renal disease worldwide. It is crucial to diagnose patients who are more sensible to develop DN for better control of the process of disease. Several factors and mechanisms contribute to the development and outcome of diabetic nephropathy. Microalbuminuria is an early marker of DN and use it as a routine for screening, but the renal damages may be happening even without microalbuminuria. There are several significant kidney damage and disease biomarkers which helps in early detection of DN. An early biomarker may allow earlier diagnosis, treatment reduces DN prevalence and slows DN progression. Therefore, this review focuses on laboratory biomarkers that are earlier, more validation of an early and specific biomarker could potentially make it possible for early diagnosis, treatment, and retardation of progression of diabetic nephropathy.

Keywords
Early detection, diabetic nephropathy, diabetes kidney disease, biomarker, early diagnosis, type 2 diabetes mellitus

Introduction
Type 2 diabetes mellitus is a pathology of heterogeneous etiology characterized by hyperglycemia resulting from defects of insulin action, insulin secretion, or both, and the population with diabetes mellitus is predicted to be about 439 million worldwide by 2030. Chronic diabetes is relative with damage, dysfunction, and failure of several organs, especially the eyes, nerves, foot, blood vessels, kidneys, and heart. Prolong diabetes has been related with microvascular complications such as retinopathy, neuropathy, and nephropathy. The microvascular complications of diabetes induce to renal damage known as diabetic nephropathy (DN), the most common complication of type 2 diabetes mellitus, and it is the leading cause of end-stage renal disease worldwide, which is associated with high morbidity and mortality. It develops in approximately 40% of patients with diabetes, after 10 years of type 2 diabetes mellitus were diagnosed. DN is characterized by persistent albuminuria (or albuminuria excretion rate of >300 mg/d or 200 μg/min) measured at least twice within three to 6 months interval, progressive decreasing in glomerular filtration rate (GFR), which often occur in association with an elevate in blood pressure, ultimately leading to end-stage renal disease.
| Author year of publication, reference | Study design | Sample | Sample size | Biomarker |
|--------------------------------------|-------------|--------|-------------|-----------|
| Amer et al., 2018 \(^{16}\) | Cross-sectional study | 85 T2DM patients were diagnosed with DN | 170 | Cystatin C (serum) |
| | | 85 T2DM patients were diagnosed without DN | | |
| Ye et al., 2021 \(^{32}\) | Prospective study | 55 patients with T2DM patients with DN | 106 | Homocysteine (serum) |
| | | 51 patients with T2DM patients without DN | | |
| Gupta et al., 2017 \(^{17}\) | Cross-sectional study | 50 T2DM patients with normoalbuminuria | 100 | Cystatin C (serum) |
| | | 50 T2DM patients with microalbuminuria | | |
| Motawi et al., 2018 \(^{23}\) | Cross-sectional study | 25 T2DM patients with normoalbuminuria | 75 | NGAL (serum) |
| | | 25 T2DM patients with microalbuminuria | bTP (serum) | |
| | | 25 healthy control subjects | Mir-130b (serum) | |
| El-Dawla et al., 2019 \(^{37}\) | Cross-sectional study | 71 DN patients categorized according to their UACR | 90 | E-cadherin (serum) |
| Li et al., 2017 \(^{18}\) | Cross-sectional study | 19 healthy control | 482 | Cystatin C (serum) |
| | | 130 T2DM patients with normoalbuminuria | | Gas6 (plasma) |
| | | 122 T2DM patients with microalbuminuria | | |
| | | 100 T2DM patients with macroalbuminuria | | |
| Veiga et al., 2020 \(^{25}\) | Cross-sectional study | 51 T2DM patients | 90 | SMAD1 (serum) |
| | | 39 healthy controls | NGAL (serum) | COLIV1A (serum) |
| Sharifi et al., 2015 \(^{30}\) | Cross-sectional study | 35 T2DM patients | 35 | NAG (urine) |
| | | | ACE (serum) | |
| Takir et al., 2016 \(^{19}\) | Cross-sectional study | T2DM patients without known overt diabetic nephropathy | 78 | Cystatin C (serum) |
| | | Group 1: GFR value <60 mL/min/1.73\(^{3}\), and MA < 30 mg/day | | TGF-1 (urine) |
| | | Group 2: GFR value <60 mL/min/1.73\(^{3}\), and MA < 30 mg/day-300 mg/day | | |
| | | Group 3: GFR value >120 mL/min/1.73\(^{3}\), and MA < 30 mg/day | | |
| | | Group 4: GFR value 90-120 mL/min/1.73\(^{3}\), and MA < 30 mg/day | | |
| Al Shawaf et al., 2019 \(^{54}\) | Cross-sectional study | 36 controls subjects | 122 | ANGPTL4 and IGFBPs (plasma) |
| | | 37 T2DM patients with normal kidney function | | |
| | | 49 T2DM patients with DN | | |
| DyabAllawi et al., 2017 \(^{24}\) | Cross-sectional study | 30 healthy control | 90 | NGAL (serum) |
| | | 30 T2DM patients with normoalbuminuria | | |
| | | 30 T2DM patients with microalbuminuria | | |
| El-Horany et al., 2017 \(^{58}\) | Cross-sectional study | 15 T2DM patients with normoalbuminuria | 45 | HSP72 (urine) |
| | | 15 T2DM patients with microalbuminuria | | |
| | | 15 T2DM patients with macroalbuminuria | | |
| | | 15 healthy control group | | |
| Shoukry et al., 2015 \(^{61}\) | Cross-sectional study | 25 T2DM patients with normoalbuminuria | 75 | MCP-1 (urine) |
| | | 25 T2DM patients with microalbuminuria | VDBP (urine) | |
| | | 25 T2DM patients with macroalbuminuria | | |
| | | 25 healthy controls | | |

T2DM: Type 2 diabetes mellitus; DN: diabetic nephropathy; urinary albumin-to-creatinine ratio; UACR; NGAL: Neutrophil gelatinase-associated lipocalin; bTP: b-trace protein; miR-130b: microRNA-130b; Gas6: Growth arrest-specific gene six; SMAD1: Suppressor of mothers against decapentaplegic type 1; COLIV1A: Type IV collagen; NAG: N-acetyl-β-D-glucosaminidase; ACE: Angiotensin-converting enzyme; TGF-1: Transforming growth factor-beta; IGFBPs: insulin-like growth factor-binding proteins family; ANGPTL4: Angiopoietin-like protein four; HSP72: Heat shock protein 72; MCP-1: Monocyte chemoattractant protein-1; VDBP: Vitamin D-binding protein; MA: microalbuminuria.
It is critical to diagnose patients who are more sensible to develop DN for better control of the process of disease. Several factors and mechanisms enhance to the development and outcome of diabetic nephropathy. Albuminuria has been one of the biomarkers to screen renal function and it has generally been examined to primarily reflect glomerular injury and increased glomerular permeability to macromolecules. However, it may not be detectable in early stage. Albuminuria has lots of limitations such as larger variability and low sensitivity, it cannot predictably lead to a renal outcome nor are specific for DN. There are several significant kidney damage and disease biomarkers which helps in early detection of DN. Biomarkers are defined as characteristic factors that can be objectively measured and assessed as an indicator of normal physiology or pathogenic processes. Examples of biomarkers are proteins, lipids, microRNAs, genomic, metabolic or proteomic patterns, electrical signals, imaging determinations, and cells present on a urine analysis.

An early biomarker may allow earlier diagnosis, treatment reduces DN prevalence and slows DN progression, thereby raising life expectancy among people with diabetes while increasing healthcare spending by less than one percent. A several of biological markers associated with diabetic nephropathy were found in recent years, which was significant for predicting the occurrence and development of the disease. Therefore, this review focuses on laboratory biomarkers that are earlier, more specific and sensitive biomarkers with greater predictability than microalbuminuria or those appearing at that time for early detection of DN.

Materials and methods

The researcher performed a review of the literature with Medline, Google Scholar, and Cochrane Library databases search for English language and human study articles registered from January 2011 to June 2021. The researcher used the following search terms: “early detection,” “diabetic nephropathy,” “Diabetes kidney disease,” “biomarker,” “early diagnosis,” and “type 2 diabetes mellitus” The keywords were searched alone or in combination with other keywords.

The abstracts and conference proceeding from the ICS annual meetings were also searched. Abstracts presented at international conferences and additional relevant publications were selected from the reference lists of identified articles were also included. No language restriction was defined. Abstract and conventional reports were excluded. Our search identified a total of 13 studies that have been published to date.

Result

Various biomarkers have been found to be associated with early detection of diabetic nephropathy, including the following (Table 1).

Serum cystatin C

Cystatin C, a 13 kDa cysteine protease inhibitor, a small protein that freely filtered by the renal glomeruli, is a novel biomarker of kidney failure. Cystatin C has been associated with the decrease of eGFR and predictors of the progression of type 2 DN. Serum cystatin C is a marker of kidney function. The mean serum cystatin C level was higher in diabetic nephropathy patients (1.87 ± 0.51 mg/L) than non-diabetes nephropathy (1.025 ± 0.30 mg/L), and the difference was significant with p-value <0.001. The results revealed a significant correlation between serum cystatin C with creatinine (r = 0.55; p < 0.001) was higher in all the patients who had an abnormally high serum creatinine level. The study suggested that serum cystatin C measurement is useful for the early detection of renal impairment in a way better than serum creatinine in the patients with diabetes. Another study showed that the mean serum cystatin C values in type 2 diabetes with normoalbuminuria were 1.73 and in type 2 diabetes with microalbuminuria were 2.07. The results show that the serum cystatin C values were raised in the patients with microalbuminuria. The study suggested that serum cystatin C may be considered as an early marker than microalbuminuria and serum creatinine. Emphasizing in serum cystatin C was significantly higher in diabetic patients with microalbuminuria or macroalbuminuria, as compared with diabetic subjects with normoalbuminuria. One study reported that serum cystatin C level was significantly higher in normoalbuminuric group and was found to negatively correlate with eGFR in group two patients (r = −0.892, p < 0.001). Finally, there was a negative correlation between eGFR and serum cystatin C in all the patient groups (r = −0.726, p = 0.001). The study suggested that serum cystatin C level was indicated to be used as an early biomarker of diabetic nephropathy. All these data suggest that serum cystatin C is a promising biomarker for early DN in type 2 diabetes.

Neutrophil gelatinase-associated lipocalin

Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa molecule which was produced in the distal nephron and increased in response to kidney injury within a few hours after damaging. NGAL excretion in serum and urine were found to be early predictive biomarkers of acute kidney injury. The appearance of NGAL in the urine may indicate early glomerular injury, and this has been showed at earlier stage than the appearance of microalbuminuria, the gold standard marker for early DN. Recent study reported that serum NGAL was significantly higher in T2DM with microalbuminuria group compared to T2DM with normalalbuminuria and control groups with significant positive correlation with age and duration of DM. The best cut-off
value of NGAL for early detection of DN is 77.72 ng/mL with sensitivity 96%, specificity 80%, PPV 82.6%, NPV 95.24%, and accuracy 88%. Another study found that the mean value of serum NGAL was significantly higher in microalbuminuria than normal albuminuria and healthy control group ($p < 0.05$). Another study including non-diabetic subjects with aged 21 years or older. The type 2 DM group consisted of patients diagnosed with Type 2 DM for at least 5 years without impaired renal function, aged $\geq 21$ years and under pharmacological treatment for DM2. Peripheral blood NGAL gene expression was increased in patients with type 2 DM compared with healthy individuals (type 2 DM $0.09758 \pm 0.1914 \times 2^{-\Delta CQA}$ vs CTL $0.02293 \pm 0.04578$). The results showed a positive correlation between serum NGAL and HbA1c in T2DM patients with normoalbuminuria, which is in agreement with DyabAllawi et al. 2017 who showed significant correlation between serum NGAL and HbA1c % ($r = 0.394$, $p = 0.03$)

NGAL is filtered from plasma through glomerular filtration and after filtration the NGAL is reabsorbed by endocytosis via the megalin system in proximal tubule. When proximal tubule is injured by tubular necrosis filtered NGAL can leave tubular reabsorption and secreted in urine, high serum NGAL and high filtered saturates tubular capacity that lead to increase urinary and serum NGAL, so that it is recommended that serum NGAL can be used as a biomarker of glomeruli injury which precedes the appearance of microalbuminuria.

**N-acetyl-β-D-glucosaminidase**

N-acetyl-β-D-glucosaminidase (NAG), an enzyme (MW 130 kDa) involved in carbohydrate metabolism, cannot be filtered from blood through an intact glomerular membrane due to its high molecular weight (140 kDa), thus presence in urine is exclusively secreted by tubular cells lysosomes of the proximal tubule epithelial cells. Its activity detected in urine may reflect an early sign of renal disorder. One study showed that urine NAG level in the diabetic group was higher compared with controls ($p < 0.05$), which indicates that the elevated urine NAG, as an early indicator of renal damage.

**Serum homocysteine**

Homocystein (Hcy) is the intermediate product of cysteine and methionine. One study showed that the serum Hcy levels were $15.49 \pm 5.40$ and $9.23 \pm 3.15$ μmol/L for DN and Type 2 DM patients, respectively, which indicated that serum Hcy in DN was higher than Type 2 DM patients and correlated with patient’s renal damage. Applying serum Hcy as the reference, the diagnostic sensitivity, specificity, and AUC were 84.31 (71.41–92.98) %, 74.55 (61.00–85.33) %, and 0.85 (0.78–0.92) %, respectively, with the cut-off value between DN and Type 2 DM groups is 12.08, serum Hcy can also be used as a serological marker for early diagnosis of DN with relatively high sensitivity and specificity.

**b-trace protein**

b-trace protein (bTP), known as lipocalin prostaglandin D2 synthase (L-PGDS), is an emerging marker of GFR. It is also a low-molecular-weight glycoprotein that belongs to the lipocalin superfamily. One study reported that bTP was significantly elevated in Type 2 DM patients with microalbuminuria compared with Type 2 DM patients with normoalbuminuria and control subjects. They suggest that serum bTP as glomerular and tubular markers, respectively, may be reliable and independent biomarkers for early detection of DN.

**microRNA-130b**

MicroRNA-130b (miR-130b) has been shown to play roles in mesenchymal differentiation, hypoxic response immune cell function, modulation, and aging process. One study showed that serum miR-130b was significantly lower in Type 2 DM with microalbuminuria group than that in Type 2 DM with normalbuminuria and control groups, and its level was markedly and gradually declined in the Type 2 DM patients with normoalbuminuria group and Type 2 DM with microalbuminuria group. So, reduced serum miR-130b level can be appraised as a good predictor for DN even before the presence of albuminuria in view of its reno-protective role by inhibiting lipid peroxidation reaction, renal fibrosis, chronic inflammation, and extracellular matrix deposition.

**E-cadherin levels**

E-cadherin is a transmembrane integral protein which is detected at the adherent junction of the epithelial cells. It is plenty in the distal tubules. In the early stages of epithelial-to-mesenchymal transition, losing of E-cadherin expression occurs and the separation of cells within the epithelial sheet happens. One study reported that E-cadherin levels were significantly declined in all groups (0.94, 0.52, and 0.14 ng/mL in normoalbuminuria, microalbuminuria, and macroalbuminuria groups; respectively), when compared with control group. UACR was negatively correlated with E-cadherin. ROC curve analyses showed that the AUC to diagnose established microalbuminuria using E-cadherin was 0.998 (95% CI 0.932–1). The study suggests that serum E-cadherin could be considered as reliable markers involved in DN pathogenesis and coordinated to its stages.

**Periostin**

Periostin is one of markers lead expression of mesenchymal phenotype in renal cells. It is discharged when distal
tubules are injured. It was detected that, during the renal injury, peristin was extremely expressed in tubulointerstitial parts. A recent study showed that peristin levels, nonsignificant increase in normoalbuminuria (0.32 ng/mL) than control group (0.3 ng/mL) was observed. There was a significant rise in other groups with the highest values in macroalbuminuria group (1.66 ng/mL). Urinary albumin-to-creatinine ratio (UACR) was positively correlated with peristin. Receiver operating characteristic (ROC) curve analyses expressed that the AUC to diagnose established microalbuminuria using peristin was 0.833 (95% CI 0.709–0.919). The study suggests that peristin could be considered as reliable biomarkers involved in DN pathogenesis and coordinated to its stages.37

**Growth arrest-specific gene 6 (Gas 6)**

Growth arrest-specific gene 6 (Gas 6) is a newly found vitamin K-dependent protein, interacting with the TAM family (Tyro-3, Axl, and Mer).40 Gas/TAM signaling has been revealed to be involved in the pathogenesis of diabetic renal disease.41 One study reported that plasma Gas six concentration was significantly lower in diabetic patients with microalbuminuria or macroalbuminuria, as compared with diabetic patients with normoalbuminuria. Gas six was inversely correlated with BMI, WHR, and HbA1c. Multivariate logistic regression analysis showed that, after adjusted for established diabetes risk factors, higher plasma Gas six was significantly associated with a reduced risk of DN. Receiver operating characteristic curve analysis showed that Gas 6 with a cut-off value of 9.435 ng/mL (86.1% sensitivity and 84.6% specificity) was a marker for early detection and diagnosis of DN.18

**Suppressor of mothers against decapentaplegic type 1**

Suppressor of mothers against decapentaplegic (SMADs) are intracellular proteins capable of regulating transcription factors and expression of target genes; once activated, these proteins migrate to the nucleus, where they trigger or suppress the transcription of different target genes.42 Recent studies have found that SMADs can be detected in the urine of patients with DN.43 A study revealed that gene expression data: peripheral blood SMAD1 (blood: DM2 0.01102 ± 0.04059 vs CTL 0.0001317 ± 0.0003609; urine: DM2 0.7195 ± 2.344 vs CTL 0.09812 ± 0.4755). These genes demonstrated perfect specificity and sensitivity in the receiving operating characteristic curve evaluation. They suggest the potential use of SMAD1 gene expression in peripheral blood and urine samples as early biomarkers of DN.25

**Type IV collagen**

Type IV collagen (COLIV) is a protein that is part of the base of basement membranes. It is synthesized mostly by, mesangial cells, epithelial cells, and glomerulus podocytes in the kidney. COLIV contributes to the formation of the glomerular filtration barrier that is essential for the glomerular perm selectivity to proteins.44 Increased COLIV expression in renal glomeruli or tubules has been indicated to mark an advanced stage of kidney function loss in Type 2 DM.45 In the assessment of COLIV1A gene expression, they identified that only four colleagues with diabetes expressed this gene in peripheral blood and three expressed this gene in urine sediment. Among the healthy colleagues, none expressed COLIV1A in either peripheral blood or urine sediment. In these patients, they found no correlation between the expression of this gene and biochemical or any of the other studied parameters.25

**Angiotensin-converting enzyme**

The urinary enzymes which have low activity in urine in normal status and may rise after renal tubular cells injuries can be used for the assessment of the kidney function.46 There were various studies reported that angiotensin-converting enzyme (ACE) activity can cause vascular smooth muscle cell proliferation and also leads the release of platelet-derived growth factor and transforming growth factor which among patients in diabetic vasculopathy.47 A study showed that mean serum ACE levels in the diabetic group was higher than control groups (p < 0.001) but urine ACE levels in diabetes patients did not differ between two group. This study revealed that serum ACE, as factors involved in vascular function, in diabetic patients were significantly higher than in healthy controls.30

**Transforming growth factor-beta**

Transforming growth factor-beta (TGF-1) is relative in DN pathogenesis. It causes mesangial extension by promoting renal cellular hypertrophy and by leading the extracellular matrix expansion.48 Urinary TGF-1 levels are raised as commensurate to the severity of the nephropathy.49 The results of serum and urine TGF-1, they found that the levels in group 2 (GFR value <60 mL/min/1.73^3, and microalbuminuria (MA) < 30 mg/day-300 mg/day) were significantly higher than group 4 (GFR value 90–120 mL/min/1.73^3, and MA < 30 mg/day) (p = 0.012; p = 0.012). In three patient groups (GFR value >120 mL/min/1.73^3, and MA < 30 mg/day), which do not have MA in their study, they have found the serum and urine TGF-1 levels were significantly higher in the groups with MA.19 Previous studies showed that TGF-1 concentration from renal vein was found positive in diabetic patients50 and TGF-1 level...
from urine in the diabetic patients raised fourfold than the non-diabetic patients. On the other hand, the result of this study was different from previous study, increased urine TGF-1 excretion was demonstrated in all diabetic patients regardless of MA status.\(^{19}\)

**Angiopoietin-like protein 4 and insulin-like growth factor-binding proteins family (IGFBPs)**

Angiopoietin-like protein 4 (ANGPTL4) is a glycoprotein (=45–65 kDa) emitted by a wide range of cells such as hepatocytes, adipocytes, macrophages, myocytes, endothelial, and intestinal cell.\(^{51}\) Insulin-like growth factor-binding proteins family (IGFBPs), can enhance development of the diabetic kidney syndrome. This group of proteins comprises six high-affinity binding proteins (IGFBP1–IGFBP6).\(^{52}\) At a state of diabetic kidney syndrome, renal IGFBP1 was found to rise at both protein levels and mRNA. Although the involvement of IGFBP3 in diabetic microalbuminuria and DN has been studied also.\(^{53}\) ANGPTL4 level was raised in people with DN (241.56 ± 14.1 μg/mL) compared to the control group (178.43 ± 24.09 μg/mL). The increase in ANGPTL4 related with clinical parameters of DN including albumin-to-creatinine ratio \((r = 0.271, p = 0.002)\), serum creatinine \((r = 0.381, p = 0.0001)\), and eGFR \((r = -0.349, p < 0.0001)\). Furthermore, ANGPTL4 related positively with both IGFBP1 \((r = 0.202, p = 0.026)\) and IGFBP4 \((r = 0.364, p < 0.0001)\). Multiple regression analysis presented increased IGFBP1 and TG as predictors of higher ANGPTL4 in patients with DN. In patients with Type 2 DM, only IGFBP1 acted as a positive predictor of an increase in ANGPTL4. In this study, their data revealed a significant increase in circulating ANGPTL4, IGFBP1, and IGFBP4 in patients with DN. The elevation in ANGPTL4 correlated significantly with clinical markers of DN such as serum creatinine, ACR, and eGFR, as well as IGFBP1 and IGFBP4. Totally, this supports ANGPTL4 as a biochemical marker for the detection of a diabetic kidney disease in Type 2 DM patients.\(^{54}\)

**Heat shock protein 72**

Heat shock protein 72 (HSP72) is released in response to stressor exposure and potently activates the inflammasome.\(^{55}\) HSP72 belongs to HSP70 family that functions as a molecular chaperone in transport, protein folding, and degradation.\(^{56}\) It has been documented that urinary HSP72 is a good marker for loss of tubular cell integrity.\(^{57}\) One study presented that uHSP72 levels were significantly increased in both microalbuminuric and macroalbuminuric diabetes compared with normoalbuminuric diabetes and healthy controls, indicating its positive relation with progression of disease. Furthermore, the significant rise in uHSP72 levels in the normoalbuminuric diabetes compared with healthy controls. ROC curve was used to evaluate the specificity and sensitivity of uHSP72 for detection of DN, as defined by the UACR. The optimal cut-off point for uHSP72 was 24.9 pg/mL with specificity 87% and sensitivity 90%, for discriminating DN from Type 2 DM patients. The results of this study suggested that urinary level of HSP72 may be considered as non-invasive diagnostic biomarker for early detection of DN, and it may be a good indicator of diabetic kidney injury progression.\(^{58}\)

**Monocyte chemoattractant protein-1**

Monocyte chemoattractant protein-1 (MCP-1) is a one member of the CC chemokine family produced by a variety of cell types, including mesangial cells, glomerular endothelial cells, tubular epithelial cells, and monocytes in response to inflammatory cytokines (IL-1, TNFα, and INFγ).\(^{59}\) Previous evidence has investigated the role of MCP-1 in DN and presented it as a major factor influencing macrophage recruitment and accumulation in renal disease. Some studies have reported that urinary monocyte chemoattractant protein-1 (uMCP-1) levels are increased in inflammatory renal diseases and diabetic nephropathy.\(^{60}\) One study showed that, a significant elevation in the uMCP-1 levels was found in macroalbuminuric \((p < 0.001)\) and microalbuminuric \((p < 0.01)\) diabetic patients compared to that in normoalbuminuric diabetic patients and control subjects \((p < 0.001)\). Correlation study showed that uMCP-1 was importantly positively related to urinary albumin/creatinine ratio \((r = 0.968, p < 0.001)\), serum urea \((r = 0.461, p = 0.001)\), and serum creatinine \((r = 0.475, p = 0.001)\) and significantly inversely correlated to glomerular filtration rate \((r = -0.983, p < 0.001)\). Receiver operating characteristic (ROC) curve analysis of uMCP-1 levels for early detection and diagnosis of DN showed that the cut-off value of uMCP-1 was 110 pg/mg with 100% specificity and 92% sensitivity. The findings suggest that uMCP-1 may be considered as novel potential diagnostic biomarkers for the early detection of diabetic nephropathy.\(^{61}\)

**Vitamin D-binding protein**

Vitamin D-binding protein (VDBP), is a 58–kDa glycoprotein and is show in the serum at a concentration of 300–600 mg/mL. In the kidney, VDBP is involved in the endocrine biosynthetic process of 1,25-dihydroxyvitamin D \([1,25(OH)2D]\) within renal proximal tubules.\(^{62}\) Current article revealed that urine vitamin D-binding protein (uVDBP) is raised compared to that in non-diabetics, especially when albuminuria is present.\(^{63}\) A significant elevation in the uVDBP levels was found in macroalbuminuric \((p < 0.001)\) and microalbuminuric \((p < 0.01)\) diabetic patients compared to that in normoalbuminuric diabetic
patients and control subjects ($p < 0.001$). Correlation study showed that uVDBP was significantly positively correlated to urinary albumin/creatinine ratio ($r = 0.973$, $p < 0.001$), serum urea ($r = 0.456$, $p = 0.002$), and serum creatinine ($r = 0.448$, $p = 0.004$) and significantly inversely correlated to glomerular filtration rate ($r = −0.988$, $p < 0.001$). Receiver operating characteristic (ROC) curve analysis of uVDBP levels for early diagnosis and detection of DN revealed that the cut-off value of uVDBP was 550 ng/mg with 84% specificity and 96% sensitivity. The results of the present study suggest that uVDBP may be appraised as novel diagnostic biomarkers for the early detection of diabetic nephropathy. The role of VDBP in the pathogenesis of DN is not clear. In diabetes mellitus patients with DN contributed urinary loss of VDBP and led to Vitamin D deficiency, which may have a significant role in the progressive loss of kidney function and is independently related with the development of DN.

**Conclusion**

Microalbuminuria is an early marker of DN. Measurement of microalbuminuria is a routine clinical practice for screening, but the injury to the kidney may be happening even without microalbuminuria. It is significant to implement different strategies for earlier detection of DN because of an early biomarker may allow earlier diagnosis, treatment reduces DN prevalence and slows DN progression and increasing quality of life among people with diabetes mellitus. Mostly biomarkers were significantly higher in type 2 diabetic patients with normoalbuminuria, microalbuminuria, and macroalbuminuria compared with non-diabetic group and could be used as early markers before the development of DN. However, multicenter prospective studies are still needed to confirm these biomarkers in order to use for screening in everyday setting.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Excellence Center of Community Health Promotion, School of Nursing, Walailak University.

**ORCID iD**

Sopida Thipsawat  
https://orcid.org/0000-0002-7666-7384

**References**

1. Brijesh M and Saurav P. Comparative study of significance of serum cystatin-C, serum creatinine and microalbuminuria estimation in patients of early diabetic nephropathy. J Diabetes Metab 2015; 6: 2.
2. Shaw JE, Sicree RA and Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4–14.
3. Balaji R, Duraisamy R and Kumar MP. Complications of diabetes mellitus: A review. Drug Invent Today 2019; 15: 12.
4. Beckman JA and Creager MA. Vascular complications of diabetes. Circ Res 2016; 118: 1771–1785.
5. Long AN and Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens 2011; 13: 244–251.
6. Maggiore U, Budde K, Heemann U, et al. Long-term risks of kidney living donation: review and position paper by the ERA-EDTA DESCARTES working group. Nephrol Dial Transplant 2017; 32: 216–223.
7. Alicic RZ, Rooney MT and Tuttle KR. Diabetic kidney disease. Clin J Am Soc Nephrol 2017; 12: 2032–2045.
8. Selby NM and Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 2020; 22: 3–15.
9. Sternlicht H and Bakris GL. Management of hypertension in diabetic nephropathy: how low should we go?. Blood Purif 2016; 41: 139–143.
10. Liu R, Li G, Cui X-F, et al. Methodological evaluation and comparison of five urinary albumin measurements. J Clin Lab Anal 2011; 25: 324–329.
11. Brenner BM, Hostetter TH and Humes HD. Molecular basis of proteinuria of glomerular origin. New Engl J Med 1978; 298: 826–833.
12. Jim B, Santos J, Spath F, et al. Biomarkers of diabetic nephropathy, the present and the future. Curr Diabetes Rev 2012; 8: 317–328.
13. Bonventre JV. Current Biomarkers in Kidney Disease: Dawning of a New Era. ASN Kidney News, 2014, p. 7–8.
14. Thornton Snider J, Sullivan J, van Eijndhoven E, et al. Lifetime benefits of early detection and treatment of diabetic kidney disease. PloS One 2019; 14: e0217487.
15. Kim SS, Song SH, Kim JJ, et al. Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care 2013; 36: 656–661.
16. Amer AH and Haridas N. Early Diagnostic Markers in Diabetic Nephropathy Patients. J Clin Diag Res 2018; 12.
17. Gupta K, Nayyar SB, Sachdeva J, et al. Cystatin C in the early diagnosis of diabetic nephropathy and its correlation with albuminuria. Int J Adv Med 2017; 4: 56–59.
18. Li W, Wang J, Ge L, et al. Growth arrest-specific protein 6 (Gas6) as a noninvasive biomarker for early detection of diabetic nephropathy. Clin Exp Hypertens 2017; 39: 382–387.
19. Takir M, Unal AD, Kostek O, et al. Cystatin-C and TGF-β levels in patients with diabetic nephropathy. Nefrologia 2016; 36: 653–659.
20. Papadopoulou- Marketou N, Skevaki C, Kosteria I, et al. NGAL and cystatin C: two possible early markers of diabetic nephropathy in young patients with type 1 diabetes mellitus: one year follow up. *Hormones (Athens, Greece)* 2015; 14: 232–240.

21. Shaker O, El-Shehaby A and El-Khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. *Angiology* 2010; 61: 731–736.

22. Al-Refai AA, Tayel SI, Ragheb A, et al. Urinary neutrophil gelatinase associated lipocalin as a marker of tubular damage in type 2 diabetic patients with and without albuminuria. *Open J Nephrol* 2014; 2014.

23. Motawi TK, Shehata NI, ElNokeety MM and El-Emady YF. Neutrophil gelatinase-associated lipocalin (NGAL) in early detection of diabetic nephropathy. *Diabetes Res Clin Pract* 2018; 136: 150–158.

24. DyabAllawi AA, Nada SZ and Turki KM. Neutrophil gelatinase-associated lipocalin (NGAL) in early detection of nephropathy in type 2 diabetic Iraqi patients. *J Fac Med Baghdad* 2017; 59: 74–78.

25. Veiga G, Alves B, Perez M, et al. NGAL and SMAD1 gene expression in the early detection of diabetic nephropathy by liquid biopsy. *J Clin Pathol* 2020; 73: 713–721.

26. van Deursen VM, Damman K, Voors AA, et al. Renal tubular damage. *Comorbidity Heart Failure* 2013; 52.

27. Singer E, Markó L, Paragas N, et al. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. *Acta Physiol* 2013; 207: 663–672.

28. Bolignon D., Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. *Clin J Am Soc Nephrol* 2009; 4: 337–344.

29. Nauta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. *Diabetes Care* 2011; 34: 975–98198.

30. Sharifi AM, Zare B, Keshavarz M, et al. Urinary N-acetyl-β-D-glucosaminidase (NAG) activity in the early detection of diabetic nephropathy. *Int J Diabetes Developing Countries* 2015; 35: 369–374.

31. Aguilar B, Rojas JC and Collados MAT. Metabolism of homocysteine and its relationship with cardiovascular disease. *J Thromb Thrombolysis* 2004; 18: 75–87.

32. Ye B, Zhu X, Zeng Z, et al. Clinical significance of serum homocysteine as a biomarker for early diagnosis of diabetic nephropathy in type 2 diabetes mellitus patients. *Pteridines* 2021; 32: 11–16.

33. Reidy K, Kang HM, Hostetter T, et al. Molecular mechanisms of diabetic kidney disease. *J Clin Invest* 2014; 124: 2333–2340.

34. Zhang H, Yang H, Zhang C, et al. Investigation of microRNA expression in human serum during the aging process. *The Journals Gerontol Ser A* 2015; 70: 102–109.

35. Stephenson RO, Yamanaka Y and Rossant J. Disorganized epithelial polarity and excess trophoderm cell fate in preimplantation embryos lacking E-cadherin. *Development* 2010; 137: 3383–3391.

36. Lamouille S, Xu J and Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol* 2014; 15: 178–196.

37. El-Dawla NMQ, Sallam A-AM, El-Hefnawy MH, et al. E-cadherin and peristin in early detection and progression of diabetic nephropathy: epithelial-to-mesenchymal transition. *Clin Exp Nephrol* 2019; 23: 1050–1057.

38. Chijimatsu R, Kunugiza Y, Taniyama Y, et al. Expression and pathological effects of peristin in human osteoarthrits cartilage. *BMC Musculoskeletal Disorders* 2015; 16: 1–2.

39. Satirapoj B, Wang Y, Chamberlin MP, et al. Peristin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. *Nephrol Dial Transplant* 2012; 27: 2702–2711.

40. Hafizi S and Dahlbäck B. Gas6 and protein S. *FEBS J* 2006; 273: 5231–5244.

41. Nagai K, Arai H, Yanagita M, et al. Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. *J Biol Chem* 2003; 278: 18229–18234.

42. Moustakas A and Heldin C-H. Mechanisms of TGFβ-induced epithelial-mesenchymal transition. *J Clin Med* 2016; 5: 63.

43. Abe H, Matsubara T, Arai H and Doi T. Role of Smad1 in diabetic nephropathy: molecular mechanisms and implications as a diagnostic marker. *Histology and Histopathology* 2011; 26: 531–541.

44. Chioran A, Duncan S, Catalano A, et al. Collagen IV trafficking: the inside-out and beyond story. *Dev Biol* 2017; 431: 124–133.

45. Wang J-Y, Gao Y-B, Zhang N, et al. miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. * Mol Cell Endocrinol* 2014; 392: 163–172.

46. Mohammadi-Karakani A, Asgharzadeh-Haghighi S, Ghazikhansari M, et al. Determination of urinary enzymes as a marker of early renal damage in diabetic patients. *J Clin Lab Anal* 2007; 21: 413–417.

47. Lardizabal JA and Deedwania PC. The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. *Curr Cardiology Reports* 2010; 12: 464–471.

48. Chang AS, Hathaway CK, Smithies O, et al. Transforming growth factor-β1 and diabetic nephropathy. *Am Journal Physiology. Ren Physiology* 2016; 310: F689–F696.

49. Ibrahim S and Rashed L. Estimation of transforming growth factor-beta 1 as a marker of renal injury in type II diabetes. *Saudi Medical Journal* 2007; 28: 519–523.

50. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. *Diabetes* 1997; 46: 854–859.
51. Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys Acta (Bba) - Mol Cel Biol Lipids 2014; 1841: 919–933.

52. Rajwani A, Ezzat V, Smith J, et al. Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes 2012; 61: 915–924.

53. Vasylyeva TL and Ferry RJ Jr. Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy. Diabetes Res Clin Pract 2007; 76: 177–186.

54. Al Shawaf E, Abu-Farha M, Devarajan S, et al. Angptl4: a predictive marker for diabetic nephropathy. J Diabetes Research 2019; 2019: 4943191.

55. Maslanik T, Mahaffey L, Tanamura K, et al. The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure. Brain Behav Immun 2013; 28: 54–62.

56. Marzec L., Zdrojewski Z, Liberek T, et al. Expression of Hsp72 protein in chronic kidney disease patients. Scand J Urol Nephrol 2009; 43: 400–408.

57. Mueller T, Bidmon B, Pichler P, et al. Urinary heat shock protein-72 excretion in clinical and experimental renal ischemia. Pediatr Nephrol 2003; 18: 97–99.

58. El-Horany HE, Abd-ellatif RN, Watany M, et al. NLRP3 expression and urinary HSP72 in relation to biomarkers of inflammation and oxidative stress in diabetic nephropathy patients. IUBMB Life 2017; 69: 623–630.

59. Rovin BH, Yoshiumura T and Tan L. Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J Immunology (Baltimore, Md: 1950) 1992; 148: 2148–2153.

60. Banba N, Nakamura T, Matsumura M, et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000; 58: 684–690.

61. Shoukry A, Bdeer SE-A and El-Sokkary RH. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus. Mol Cell Biochem 2015; 408: 25–35.

62. Chun RF, Peercy BE, Adams JS, et al. Vitamin D Binding Protein and Monocyte Response to 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Analysis by Mathematical Modeling. PloS One 2012; 7: e30773.

63. Thraillkill KM, Jo C-H, Cockrell GE, et al. Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency?. J Clin Endocrinol Metab 2011; 96: 142–149.

64. Tahranii AA, Ball A, Shepherd L, et al. The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. Int J Clin Pract 2010; 64: 351–355.

65. Diaz A, Mainous AG, Carek PJ, et al. The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 2009; 22: 521–527.